A common problem for patients receiving total knee arthroplasty (TKA) is postoperative functional impairment of the joint. This is minimized in bicruciate-retaining (ACL preserving) knee replacements, due to the important role of the anterior cruciate ligament (ACL) in normal kinematic patterns of the knee. We explore ACL sparing TKA by estimating the fraction of osteoarthritic TKA patients with a compatible ACL (assessed intraoperatively), while also examining potential preoperative indicators of ACL status. We retrospectively examined 498 patients with a primary diagnosis of osteoarthritis who underwent a TKA by one surgeon between September 2013 and March 2015. Exclusion criteria included a prior TKA, a unicompartmental knee replacement, or inflammatory arthritis. Extensive preoperative data (within four months of surgery) for each patient was collected (anatomical alignment, extension, flexion, range of motion (ROM), Lachman test, and BMI) in addition to de-identified demographic data. The intraoperative assessment of ACL status (normal/functionally intact, compromised/deficient, or absent) was then obtained from our local database and compared with the preoperative data. IRB exemption was obtained to retrospectively collect data.Introduction
Method
Pain control following total knee arthroplasty (TKA) heavily influences timing of mobilization and rehabilitation postoperatively as well as length of hospital stay. Recently, periarticular injection of liposomal bupivacaine (EXPAREL®; Pacira Pharmaceuticals, Inc., San Diego, California) has demonstrated pain relief comparable to femoral nerve block for postoperative analgesia in TKA with earlier mobilization and shortened hospital stay. In order to better explore the use of EXPAREL® in TKA, we standardized the postoperative analgesia to intraoperative periarticular injection of multimodal pain management, which is a recommended postoperative method of pain control in TKA. We studied the effectiveness of periarticular EXPAREL® in TKA postoperative pain control, including impact on early mobilization and length of hospital stay, compared to another local analgesic (Ropivacaine) when both are used as part of a multimodal pain management approach. We performed a double blind, randomized, controlled, prospective, IRB-approved study that enrolled 96 participants who underwent a unilateral TKA by one surgeon between May 2014 and March 2015. The two randomized groups were as follows: group 1 (control group) was given the standard intra-articular “pain cocktail” injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation and group 2 (study group) was given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into an 80cc preparation as well as an injection of EXPAREL®, 20cc of 1.3% EXPAREL®, to total 100cc. All patients included in the study were determined to be opioid naïve as described by the Food and Drug Administration criteria. Patients were treated with the same postoperative pain management protocol as well as the same post-operative physical therapy program. The consumption of oral and intravenous narcotics at specific time points as well as total use was recorded during hospital stay. We recorded Visual Analog Pain scores, hours to ambulate 100 feet and length of hospital stay (hours). Both the investigator and the patient were blinded as to which group the patient was randomized, making this a double blind study.Introduction
Methods
